Therapeutic applications of sulfamates

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 9, 2004, Pages 1273-1308

  Winum, Jean Yves ^a   Scozzafava, Andrea ^b   Montero, Jean Louis ^a   Supuran, Claudiu T ^b  

^a UNIV MONTPELLIER   (France)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Anti obesity drug; Antibiotic; Anticancer drug; Anticonvulsant; Antiviral agent; Carbonic anhydrase inhibitor; COUMATE; Steroid; Sulfamate; Sulfatase inhibitor; Topiramate

Indexed keywords

5' O SULFAMOYL ADENOSINE; 667 COUMATE; ADENOSINE DERIVATIVE; AMINO ACID TRANSFER RNA LIGASE INHIBITOR; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ASCAMYCIN; AVASIMIBE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE V; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; DEALANYLASCAMYCIN; ENZYME INHIBITOR; ISOENZYME; NUCLEOCIDIN; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STERYL SULFATASE; STERYL SULFATASE INHIBITOR; SULFAMIC ACID; SULFONAMIDE; SULFUR ACID DERIVATIVE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROSCLEROSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG TARGETING; DRUG USE; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HYPERLIPIDEMIA; LIPOGENESIS; NONHUMAN; OBESITY; PROSTATE CANCER; REVIEW; X RAY ANALYSIS;

EID: 4544318640     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.9.1273     Document Type: Review

References (143)

1. ABBATE F, SUPURAN CT, SCOZZAFAVA A, ORIOLI P, STUBBS MT, KLEBE G: Nonaromatic sulfonamide group as an ideal anchor for potent human carbonic anhydrase inhibitors: role of hydrogen-bonding networks in ligand binding and drug design. J. Med. Chem. (2002) 45:3583-3587.
2. NUSSBAUMER P, BILLICH A: Steroid sulfatase inhibitors. Expert Opin. Ther. Patents (2003) 13:605-625.
3. SUPURAN CT, SCOZZAFAVA A, CASINI A: Carbonic anhydrase inhibitors. Med. Res. Rev. (2003) 23:146-189.
4. SUPURAN CT, SCOZZAFAVA A: Applications of carbonic anhydrase inhibitors and activators in therapy. Expert Opin. Ther. Patents (2002) 12:217-242.
5. SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin. Ther. Patents (2000) 10:575-600.
6. SCOZZAFAVA A, OWA T, MASTROLORENZO A, SUPURAN CT: Anticancer and antiviral sulfonamides. Curr. Med. Chem. (2003) 10:925-953.
7. WEBER A, CASINI A, HEINE A, KUHN D, SUPURAN CT, SCOZZAFAVA A, KLEBE G: Unexpected nanomolar inhibition of carbonic anhydrase by COX-2 selective celecoxib: new pharmacological opportunities due to related binding site recognition. J. Med. Chem. (2004) 47:550-557.
8. NUSSBAUMER P, BILLICH A: Steroid sulfatase inhibitors. Med. Res. Rev. (2004) 24:529-576.
9. WINUM JY, VULLO D, CASINI A, MONTERO J-L, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: inhibition of cytosolic isozymes I and II and the membrane-bound, tumor associated isozyme IX with sulfamates also acting as steroid sulfatase inhibitors. J. Med. Chem. (2003) 46:2197-2204.
10. WINUM JY, VULLO D, CASINI A, MONTERO J-L, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: inhibition of transmembrane, tumor associated isozyme IX and cytosolic isozymes I and II with aliphatic sulfamates. J. Med. Chem. (2003) 46:5471-5477.
11. SPILLANE WJ, RYDER CA, WALSH MR, CURRAN PJ, CONCAGH DG, WALL SN: Sulfamate sweeteners. Food Chem. (1996) 56:255-261.
12. SCHIMMEL P, TAO J, HILL J: Aminoacyl tRNA synthetase as targets for new anti-infectives. FASEB J. (1998) 12:1599-1609.
13. VON DER HAAR E, GABIUS H-J, CRAMER F: Target directed drug synthesis: the aminoacyl-tRNA synthetases as possible targets. Angew. Chem. (Int. Ed. Engl.) (1981) 20:217-223.
14. THOMAS SO, SINGLETON VL, LOWERY JA et al.: Nucleocidin, a new antibiotic with activity against Trypanosomes.Antibiot. Ann. (1956-1957) 1957:716-721.
15. SHUMAN DA, ROBINS MJ, ROBINS RK: The synthesis of nucleoside sulfamates related to nucleocidin. J. Am. Chem. Soc. (1970) 92:3434-3437.
16. TAKAHASHI E, BEPPU T: A new nucleosidic antibiotic AT-265. J. Antibiot. (1982) 35:939-947.
17. KINI GD, HENRY EM, ROBINS RK et al.: Synthesis, structure and antiparasitic activity of sulfamoyl derivatives of Ribavirin. J. Med. Chem. (1990) 33:44-48.
18. PETERSON EM, BROWNELL J, VINCE R: Synthesis and biological evaluation of 5′-sulfamoylated purinyl carbocyclic nucleosides. J. Med. Chem. (1992) 35:3991-4000.
19. BLOCK A, COUTSOGEORGOPOULOS C: Inhibition of protein synthesis by 5′-sulfamoyladenosine. Biochemistry (1971) 10:4394-4398.
20. GUAY DR: Treatment of bacterial skin and skin structure infection. Expert Opin. Pharmacother. (2003) 4:1259-1275.
21. UEDA H, SHOKU Y, HAYASHI N et al.: X-ray crystallographic conformational study of 5′-O-[N-(L-alanyl)-sulfamoyl]adenosine, a substrate analogue for alanyl-tRNA synthetase. Biochim. Biophys. Acta (1991) 1080:126-134.
22. FORREST AK, JARVEST RL, MENSAH LM, O'HANLON PJ, POPE AJ, SHEPPARD RJ: Aminoalkyl adenylate and aminoacyl sulfamate intermediate analogues differing greatly in affinity for their cognate Staphylococcus aureus aminoacyl tRNA synthetases. Bioorg. Med. Chem. Lett. (2000) 10:1871-1874.
23. BROWN MJB, MENSAH LM, DOYLE ML et al.: Rational design of femtomolar inhibitors of isoleucyl tRNA synthetase from a binding model for pseudomonic acid-A. Biochemistry (2000) 39:6003-6011.
24. HEACOCK D, FORSYTH CJ, KIYOTAKA S, MUSIER-FORSYTH K: Synthesis and aminoacyl-tRNA synthetase inhibitory activity of prolyl adenylate analogs. Bioorg. Chem. (1996) 24:273-289.
25. BELRHALI H, YAMENCHUK A, TUKALO M et al.: Crystal structures at 2.5 Å resolution of seryl-tRNA synthetase complexed with two analogs of seryl adenylate. Science (1994) 263:1432-1436.
26. BROWN P, RICHARDSON CM, MENSAH LM et al.: Molecular recognition of tyrosinyl adenylate analogues by prokaryotic tyrosyl tRNA synthetases. Bioorg. Med. Chem. (1999) 7:2473-2485.
27. LEE J, KIM SE, LEE JY et al.: N-Alkoxysulfamide, N-hydroxysulfamide, and sulfamate analogues of methionyl and isoleucyl adenylates as inhibitors of methionyl-tRNA synthetases. Bioorg. Med. Chem. Lett. (2003) 13:1087-1092.
28. ISONO K, URAMOTO M, KUSAKABE H et al.: Ascamycin and dealanylascamycin, nucleoside antibiotics from Streptomyces sp. J. Antibiot. (1984) 37:670-672.
29. OSADA H, ISONO K: Mechanism of action and selective toxicity of ascamycin, a nucleoside antibiotic. Antimicrob. Agents Chemother. (1985) 27:230-233.
30. YU XY, HILL JM, YU G, WANG W, KLUGE AF, WENDLER P, GALLANT P: Synthesis and structure-activity relationships of a series of novel thiazoles as inhibitors of aminoacyl-tRNA synthetases. Bioorg. Med. Chem. Lett. (1999) 9:375-380.
31. SUPURAN CT, INNOCENTI A, MASTROLORENZO A, SCOZZAFAVA A: Antiviral sulfonamide derivatives. Mini-Rev. Med. Chem. (2004) 4:189-200.
32. DE CLERCQ E: Highlights in the development of new antiviral agents. Mini Rev. Med. Chem. (2002) 2:163-175.
33. DE CLERCQ E: New anti-HIV agents and targets. Med. Res. Rev. (2002) 22:531-565.
34. DE CLERCQ E: Strategies in the design of antiviral drugs. Nat. Rev. Drug Discov. (2002) 1:13-25.
35. RICHMAN DD: HIV chemotherapy. Nature (2001) 410:995-1001.
36. SUPURAN CT, CASINI A, SCOZZAFAVA A: Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents. Med. Res. Rev. (2003) 23:535-558.
37. SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents. J. Enzyme Inhib. Med. Chem. (2002) 17:69-76.
38. MASTROLORENZO A, SCOZZAFAVA A, SUPURAN CT: Small-molecule antagonists of chemokine receptors as emerging anti-HIV agents. Expert Opin. Ther. Patents (2001) 11:1245-1252.
39. VINCE R, PHAM P: The synthesis and biological evaluation of sulfamoyl nucleosides related to carbovir and AZT. Nucleos. Nucleot. (1995) 14:2051-2060.
40. JENNINGS LJ, MACCHIA M, PARKIN A: Synthesis of analogues of 5-iodo-2′-deoxyuridine-5′-diphosphate. J. Chem. Soc., Perkin Trans. 1 (1992):2197-2202.
41. CAMARASA MJ, FERNANDEZ-RESA P, GARCIA-LOPEZ MT et al.: Uridine 5′-diphosphate glucose analogues. Inhibitors of protein glycosylation that show antiviral activity. J. Med. Chem. (1985) 28:40-46.
42. FERNANDEZ-RESA P, GARCIA-LOPEZ MT, DE LAS HERAS F, SAN FELIX A, ALARCON B, CARRASCO L: Diphosphate modified antiviral analogues of uridine 5′-diphosphate glucose derivatives. Eur. J. Med. Chem. (1986) 21:245-249.
43. FIANDOR J, GARCIA-LOPEZ MT, DE LAS HERAS F et al.: Hexose-modified anti-viral analogues of uridine 5′-diphosphate glucose derivatives. Eur. J. Med. Chem. (1986) 22:59-65.
44. PEREZ-PEREZ MJ, BALZARINI J, DE CLERCQ E, CAMARASA MJ: Glycosyl-oxycarbonylaminosulfonyl-2′,3′-dideoxynucleoside derivatives as lipophilic nucleotide mimics. Synthesis and anti-HIV activity. Bioorg. Med. Chem. (1993) 1:279-284.
45. VARA PRASAD JVN, MARKOSKI LJ, BOYER FE et al.: Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety. Bioorg. Med. Chem. Lett. (1999) 9:2217-2222.
46. BARBARO G, SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr. Pharm. Des. (2004) in press.
47. HERNANDEZ-GUZMAN FG, HIGASHIYAMA T, PANGBORN W, OSAWA Y, GHOSH D: Structure of human estrone sulfatase suggests functional roles of membrane association. J. Biol. Chem. (2003) 278:22989-22997.
48. POIRIER D, CIOBANU LC, MALTAIS R: Steroid sulfatase inhibitors. Expert Opin. Ther. Patents (1999) 9:1083-1099.
49. SMITH HJ, NICHOLLS PJ, SIMONS C, LE LAIN R: Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancers. Expert Opin. Ther. Patents (2001) 11:789-824.
50. AHMED S, JAMES K, OWEN CP, SAMPSON L, PATEL CK: Review of estrone sulfatase and its inhibitors-an important new target against hormone dependent breast cancer. Curr. Med. Chem. (2002) 9:263-273.
51. PUROHIT A, WOO LW, CHANDER SK et al.: Steroid sulphatase inhibitors for breast cancer therapy. J. Steroid Biochem. Mol. Biol. (2003) 86:423-432.
52. HOWARTH NM, PUROHIT A, REED MJ, POTTER BVL: Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem. (1994) 37:219-221.
53. BILLICH A, ROT A, LAM C, SCHMIDT JB, SCHUSTER I: Immunohistochemical localization of steroid sulfatase in acne lesions: Implications for the contribution of dehydroepiandrosterone sulfate to the pathogenesis of acne. Horm. Res. (2000) 532:92-103.
54. CHEN W, THIBOUTOT D, ZOUBOULIS CC: Cutaneous androgen metabolism: basic research and clinical perspectives. J. Invest. Dermatol. (2002) 119:992-1007.
55. WOLF OT, KIRSCHBAUM C: Actions of dehydroepiandrosterone and its sulfate in central nervous system: effect on cognition and emotion in animals and humans. Brain Res. Rev. (1999) 30:264-288.
56. SUITTERS AJ, SHAW S, WALES MR et al.: Immune enhancing effects of dehydroepiandrosterone and dehydroepiandrosterone sulphate and the role of steroid sulfatase. Immunology (1997) 91:314-321.
57. AHMED S, JAMES K, OWEN CP, PATEL CK, PATEL M: Acid dissociation constant, a potential physicochemical factor in the inhibition of the enzyme estrone sulfatase (ES). Bioorg. Med. Chem. Lett. (2001) 11:899-902.
58. AHMED S, JAMES K, OWEN CP, PATEL CK, SAMPSON L: The mechanism of irreversible inhibition of estrone sulfatase (ES) through the consideration of a range of methane- and amino-sulfonate-based compounds. Bioorg. Med. Chem. Lett. (2002) 12:1279-1282.
59. AHMED S, OWEN CP, JAMES K, PATEL CK, PATEL M: Novel inhibitors of the enzyme estrone sulfatase (ES). Bioorg. Med. Chem. Lett. (2001) 11:841-844.
60. AHMED S, JAMES K, OWEN CP, PATEL CK, PATEL M: Hydrophobicity, a physicochemical factor in the inhibition of the enzyme estrone sulfatase (ES). Bioorg. Med. Chem. Lett. (2001) 11:2525-2528.
61. PATEL CK, OWEN CP, AHMED S: The design, synthesis, and in vitro biochemical evaluation of a series of esters of 4-[(aminosulfonyl)oxy]benzoate as novel and highly potent inhibitors of estrone sulfatase. Biochem. Biophys. Res. Commun. (2003) 307:778-781.
62. PATEL CK, OWEN CP, AHMED S: Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg. Med. Chem. Lett. (2004) 14:605-609.
63. NUSSBAUMER P, BILBAN M, BILLICH A: 4,4′-Benzophenone-O,O′-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg. Med. Chem. Lett. (2002) 12:2093-2095.
64. AHMED S, JAMES K, OWEN CP, PATEL CK: Design, synthesis and biochemical evaluation of AC ring mimics s novel inhibitors of the enzyme estrone sulfatase. Bioorg. Med. Chem. Lett. (2002) 12:1343-1346.
65. OKADA M, NAKAGAWA T, IWASHITA S, TAKEGAWA S, FUJII T, KOIZUMI N: Development of novel steroid sulfatase inhibitors. I. Synthesis and biological evaluation of biphenyl-4-O-sulfamates. J. Steroid Biochem. Mol. Biol. (2003) 87:141-148.
66. SAITO T, KINOSHITA S, FUJII T et al.: Development of novel steroid sulfatase inhibitors. II. TZS-8478 potently inhibits the growth of breast tumors in postmenopausal breast cancer model rats. J. Steroid Biochem. Mol. Biol. (2004) in press.
67. LI PK, MILANO S, KLUTH L, RHODES ME: Synthesis and sulfatase inhibitory activities of non-steroidal estrone sulfatase inhibitors. J. Steroid Biochem. Mol. Biol. (1996) 59:41-48.
68. KOLLI A, CHU GH, RHOSED ME, INOUE K, SELCER KW, LI PK: Development of (p-O-sulfamoyl)-N-alkanoyl-phenylalkyl amines as non-steroidal estrone sulfatase inhibitors. J. Steroid Biochem. Mol. Biol. (1999) 68:31-40.
69. CIOBANU LC, LUU-THE V, POIRIER D: Non-steroidal compounds designed to mimic potent steroid sulfatase inhibitors. J. Steroid Biochem. Mol. Biol. (2002) 80:339-353.
70. AHMED S, JAMES K, MASTRI C, ROWLANDS MG: Dual inhibitors - synthesis and evaluation of novel inhibitors of the enzymes aromatase and oestrone sulphatase, a novel therapeutic approach. J. Pharm. Pharmacol. (1999) 51S:255.
71. WOO LW, SUTCLIFFE OB, BUBERT C et al.: First dual aromatase-steroid sulfatase inhibitors. J. Med. Chem. (2003) 46:3193-3196.
72. GOLOB T, LIEBL R, VON ANGERER E: Sulfamoyloxy-substituted 2-phenylindoles: antiestrogen-based inhibitors of the steroid sulfatase in human breast cancer cells. Bioorg. Med. Chem. (2002) 10:3941-3953.
73. CHU GH, PETERS A, SELCER KW, LI PK: Synthesis and sulfatase inhibitory activities of (E)- and (Z)-4-hydroxytamoxifen sulfamates. Bioorg. Med. Chem. Lett. (1999) 9:141-144.
74. WOO LWL, PUROHIT A, MALINI B, REED MJ, POTTER BV: Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. Chem. Biol. (2000) 7:773-791.
75. MALINI B, PUROHIT A, GANESHAPILLAI D, WOO LW, POTTER BV, REED MJ: Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates. J. Steroid Biochem. Mol. Biol. (2000) 75:253-258.
76. PUROHIT A, WOO LWL, BARROW D et al.: Non-steroidal and steroidal sulfamates: new drugs for cancer therapy. Mol. Cell Endocrinol. (2001) 171:129-135.
77. NUSSBAUMER P, LEHR P, BILLICH A: 2-Substituted 4-(thio)chromenone 6-O-sulfamates: potent inhibitors of human steroid sulfatase. J. Med. Chem. (2002) 45:4310-4320.
78. NUSSBAUMER P, WINISKI AP, BILLICH A: Estrogenic potential of 2-alkyl-4-(thio)chromenone 6-O-sulfamates: potent inhibitors of human steroid sulfatase. J. Med. Chem. (2003) 46:5091-5094.
79. SCHREINER: EP, WOLFF B, WINISKI AP, BILLICH A: 6-(2-adamantan-2-ylidene-hydroxybenzoxazole)-O-sulfamate: a potent non-steroidal irreversible inhibitor of human steroid sulfatase. Bioorg. Med. Chem. Lett. (2003) 13:4313-4316.
80. BILBAN M, BILLICH A, AUER M, NUSSBAUMER P: New fluorogenic substrate for the first continuous steroid sulfatase assay. Bioorg. Med. Chem. Lett. (2000) 10:967-969.
81. PUROHIT A, VERNON KA, WAGENAAR-HUMMELINCK AE et al.: The development of A ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity. J. Steroid Biochem. Mol. Biol. (1998) 64:269-275.
82. REED JE, WOO LWL, ROBINSON JJ et al.: 2-Difluoromethylestrone 3-O-sulphamate, a highly potent steroid sulphatase inhibitor. Biochem. Biophys. Res. Commun. (2004) 317:169-175.
83. ELGER W, SCHWARZ S, HEDDEN A, REDDERSEN G, SCHNEIDER B: Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J. Steroid Biochem. Mol. Biol. (1995) 55:395-403.
84. SUZUKI RN, NEWMAN SP, PUROHIT A, LEESE MP, POTTER BV, REED MJ: Growth inhibition of multidrug-resistant breast cancer cells by 2-methoxyoestradiol-bis-sulphamate and 2-ethyloestradiol-bis-sulphamate. J. Steroid Biochem. Mol. Biol. (2003) 84:269-278.
85. HEJAZ HA, PUROHIT A, MAHON MF, REED MJ, POTTER BV: Synthesis and biological activity of the superestrogen (E)-17-oximino-3-O-sulfamoyl-1,3,5(10)-estratriene: X-ray crystal structure of (E)-17-oximino-3-hydroxy-1,3,5(10)-estratriene. J. Med. Chem. (1999) 42:3188-3192.
86. LI PK, CHU GH, GUO JP, PETERS A, SELCER KW: Development of potent non-estrogenic estrone sulfatase inhibitors. Steroids (1998) 63:425-432.
87. CIOBANU LC, BOIVIN RP, LUU-THE V, LABRIE F, POIRIER D: Potent inhibition of steroid sulfatase activity by 3-O-sulfamate 17α -benzyl (or 4′-tert-butylbenzyl)estra-1,3,5(10)-trienes: combination of two substituents at positions C3 and C17α of estradiol. J. Med. Chem. (1999) 42:2280-2286.
88. FISCHER DS, CHANDER SK, WOO LW et al.: Novel D-ring modified steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in vivo activity. J. Steroid Biochem. Mol. Biol. (2003) 84:343-349.
89. FISCHER DS, WOO LW, MAHON MF, PUROHIT A, REED MJ, POTTER BV: D-ring modified estrone derivatives as novel potent inhibitors of steroid sulfatase. Bioorg. Med. Chem. (2003) 11:1685-1700.
90. CIOBANU LC, POIRIER D: Solid-phase parallel synthesis of 17α-substituted estradiol sulfamate and phenol libraries using the multidetachable sulfamate linker. J. Comb. Chem. (2003) 5:429-440.
91. 18F]fluoroestradiol-3,17β-disulfamate. Appl. Radiat. Isot. (2002) 56:773-780.
92. 18F]fluoro-estradiol-3,17β-disulfamate in rats, tumour-bearing mice and piglets. Appl. Radiat. Isot. (2002) 57:687-695.
93. TRIPP BC, BELL CB 3RD, CRUZ F, KREBS C, FERRY JG: A role for iron in an ancient carbonic anhydrase. J. Biol. Chem. (2004) 279:6683-6687.
94. LANE TW, MOREL FM: A biological function for cadmium in marine diatoms. Proc. Natl. Acad. Sci. USA (2000) 97:4627-4631.
95. SO AK, ESPIE GS, WILLIAMS EB, SHIVELY JM, HEINHORST S, CANNON GC: A novel evolutionary lineage of carbonic anhydrase (epsilon class) is a component of the carboxysome shell. J. Bacteriol. (2004) 186:623-630.
96. LEHTONEN J, SHEN B, VIHINEN M et al.: Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family. J. Biol. Chem. (2004) 279:2719-2727.
97. PASTOREKOVA S, PARKKILA S, PASTOREK J, SUPURAN CT: Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J. Enz. Inhib. Med. Chem. (2004) 19:199-229.
98. Carbonic Anhydrase - Its Inhibitors And Activators. Supuran CT, Scozzafava A, Conway J (Eds). CRC Press, Boca Raton, FL, USA (2004):1-376.
99. SUPURAN CT: Indisulam: an anticancer sulfonamide in clinical development. Expert Opin. Investig. Drugs (2003) 12:283-287.
100. ABBATE F, CASINI A, OWA T, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. (2004) 14:217-223.
101. SUPURAN CT: Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert Opin. Ther. Patents (2003) 13:1545-1550.
102. LO YS, NOLAN JC, MAREN TH, WELSTEAD WJ, GRIPSHOVER DF, SHAMBLEE DA: Synthesis and physicochemical properties of sulfamate derivatives as topical antiglaucoma agents. J. Med. Chem. (1992) 35:4790-4794.
103. BRIGANTI F, PIERATTELLI R, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors. Part 37. Novel classes of carbonic anhydrase inhibitors and their interaction with the native and cobalt-substituted enzyme: kinetic and spectroscopic investigations. Eur. J. Med. Chem. (1996) 31:1001-1010.
104. MARYANOFF BE, NORTEY SO, GARDOCKI JF, SHANK RP, DODGSON SP: Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate and related compounds. J. Med. Chem. (1987) 30:880-887.
105. MARYANOFF BE, COSTANZO MJ, NORTEY SO et al.: Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives. J. Med. Chem. (1998) 41:1315-1343.
106. RECACHA R, COSTANZO MJ, MARYANOFF BE, CHATTOPADHYAY D: Crystal structure of human carbonic anhydrase II complexed with an anti-convulsant sugar sulphamate. Biochem. J. (2002) 361:437-441.
107. CASINI A, ANTEL J, ABBATE F et al.: Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg. Med. Chem. Lett. (2003) 13:841-845.
108. ANTEL J, WEBER A, SOTRIFFER CA, KLEBE G: Multiple binding modes observed in X-ray structures of carbonic anhydrase-inhibitor complexes and elsewhere: consequences for structure-based drug design. In: Carbonic Anhydrase - Its Inhibitors And Activators. Supuran CT, Scozzafava A, Conway J (Eds). CRC Press, Boca Raton, FL, USA (2004):45-66.
109. VICKER N, HO Y, ROBINSON J et al.: Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II. Bioorg. Med. Chem. Lett. (2003) 13:863-865.
110. HO YT, PUROHIT A, VICKER N et al.. Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates. Biochem. Biophys. Res. Commun. (2003) 305:909-914.
111. ABBATE F, WINUM JY, POTTER BV et al.: Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. Bioorg. Med. Chem. Lett. (2004) 14:231-234.
112. PASTOREKOVA S, PASTOREK J: Cancer-related carbonic anhydrase isozymes. In: Carbonic anhydrase - Its inhibitors and activators. Supuran CT, Scozzafava A, Conway J (Eds) CRC Press, Boca Raton, FL, USA (2004):253-280.
113. MASEREEL B, ROLIN S, ABBATE F, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J. Med. Chem. (2002) 45:312-320.
114. ILIES MA, MASEREEL B, ROLIN S et al.: Carbonic anhydrase inhibitors: aromatic and heterocyclic sulfonamides incorporating adamantyl moieties with strong anticonvulsant activity. Bioorg. Med. Chem. (2004) 12:2717-2726.
115. SHANK RP, GARDOCKI JF, VAUGHT JL et al.: Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia (1994) 35:450-460.
116. SILLS GJ, LEACH JP, KILPATRICK WS, FRASER CM, THOMPSON GG, BRODIE MJ: Concentration-effect studies with topiramate on selected enzymes and intermediates of the GABA shunt. Epilepsia (2000) 41:S30-S34.
117. ROSENFELD WE: Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin. Ther. (1997) 19:1294-1308.
118. HERRERO AI, DEL OLMO N, GONZALEZ-ESCALADA JR, SOLIS JM: Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacol. (2002) 42:210-220.
119. KUZNIECKY R, HO S, PAN J et al.: Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology (2002) 58:368-372.
120. REIS J, TERGAU F, HAMER HM et al.: Topiramate selectively decreases intracortical excitability in human motor cortex. Epilepsia (2002) 43:1149-1156.
121. GIBBS JW III, SOMBATI S, DELORENZO RJ, COULTER DA: Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia (2000) 41:S10-S16.
122. SKRADSKI S, WHITE HS: Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia (2000) 41:S45-S47.
123. ZULLINO DF, KRENZ S, BESSON J: AMPA blockade may be the mechanism underlying the efficacy of topiramate in PTSD. J. Clin. Psych. (2003) 64:219-220.
124. MCLEAN MJ, BUKHARI AA, WAMIL AW: Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia (2000) 41:S21-S24.
125. TAVERNA S, SANCINI G, MANTEGAZZA M, FRANCESCHETTI S, AVANZINI G: Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J. Pharmacol. Exp. Ther. (1999) 288:960-968.
126. PERUCCA E: A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol. Res. (1997) 35:241-256.
127. DODGSON SJ, SHANK RP, MARYANOFF BE: Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia (2000) 41:S35-S39.
128. FAKHOURY T, MURRAY L, SEGER D, MCLEAN M, ABOU-KHALIL B: Topiramate overdose: clinical and laboratory features. Epilepsy Behav. (2002) 3:185-189.
129. KUO RL, MORAN ME, KIM DH, ABRAHAMS HM, WHITE MD, LINGEMAN JE: Topiramate-induced nephrolithiasis. J. Endourol. (2002) 16:229-231.
130. RIBACOBA-MONTERO R, SALAS-PUIG X: Efficacy and tolerability of long term topiramate in drug resistant epilepsy in adults. Rev. Neurol. (2002) 34:101-105.
131. ARIBI AM, STRINGER JL: Effects of antiepileptic drugs on extracellular pH regulation in the hippocampal CA1 region in vivo. Epilepsy Res. (2002) 49:143-151.
132. STRINGER JL: A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat. Epilepsy Res. (2000) 40:147-153.
133. HAZEN SA, WAHEED A, SLY WS, LANOUE KF, LYNCH CJ: Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes. FASEB J. (1996) 10:481-490.
134. LYNCH CJ, FOX H, HAZEN SA, STANLEY BA, DODGSON SJ, LANOUE KF: Role of hepatic carbonic anhydrase in de novo lipogenesis. Biochem. J. (1995) 310:197-202.
135. GORDON A, PRICE H: Mood stabilization and weight loss with topiramate. Am. J. Psychiatry (1999) 156:968-969.
136. PICARD F, DESHAIES Y, LALONDE J, SAMSON P, RICHARD D: Topiramate reduces energy and fat gains in lean (Fal?) and obese (fa/fa) Zucker rats. Obesity Res. (2000) 8:656-663.
137. VULLO D, FRANCHI M, GALLORI E, ANTEL J, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. J. Med. Chem. (2004) 47:1272-1279.
138. SLISKOVIC DR, KRAUSE BR, PICARD JA et al.: Inhibitors of Acyl-CoA: cholesterol O-acyltransferase (ACAT) as hypocholesterolemic agents. The first water-soluble ACAT inhibitor with lipid-regulating activity. J. Med. Chem. (1994) 37:560-562.
139. LEE HT, SLISKOVIC DR, PICARD JA et al.: Inhibitors of Acyl-CoA: cholesterol O-acyltransferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets. J. Med. Chem. (1996) 39:5031-5034.
140. LLAVERIAS G, LAGUNA JC, ALEGRET M: Pharmacology of the ACAT inhibitor avasimibe (CI-1011). Cardiovasc. Drug. Rev. (2003) 1:33-50.
141. BURNETT JR, HUFF MW: Avasimibe Pfizer. Curr. Opin. Investig. Drugs (2002) 3:1328-1333.
142. WALSH DA, LO YS, SHAMBLEE DA, WELSTEAD WJ, NOLAN JC, GRAFF G: Methylsulfamic acid esters. A new chemical class of oral antiarthritic agents. J. Med. Chem. (1990) 33:2068-2070.
143. NOLAN JC, WALSH DA, LO Y et al.: AHR-15010: a novel anti-arthritic agent. J. Pharm. Pharmacol. (1990) 42:533-537.